These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35137394)

  • 1. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Kawata AK; Ladd MK; Lipton RB; Buse DC; Bensink M; Shah S; Hareendran A; Mannix S; Mikol D
    Headache; 2022 Feb; 62(2):159-168. PubMed ID: 35137394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).
    Kawata AK; Hareendran A; Shaffer S; Mannix S; Thach A; Desai P; Mikol DD; Ortmeier B; Bayliss M; Buse DC
    Headache; 2019 Sep; 59(8):1253-1269. PubMed ID: 31168803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
    Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
    Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
    Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
    Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
    Shao SC; Hentz J; Shank P; Leonard M; Dodick DW; Schwedt TJ
    Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
    Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
    Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
    Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
    JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
    J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
    Wang SJ; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Snellman J; Wen S; Yin F; Li Z; Su W; Yu S
    Headache; 2024 May; ():. PubMed ID: 38785393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.